Effects of a new nutraceutical substance on clinical and molecular parameters in patients with chronic venous ulceration

International Wound Journal

Volumn 13, Issue 1, 2016, Pages 88-96

  Serra, Raffaele ^a   Grande, Raffaele ^a   Butrico, Lucia ^a   Buffone, Gianluca ^a   Caliò, Francesco G ^b   Squillace, Aida ^a   Rizzo, Barbara A ^a   Massara, Mafalda ^c   Spinelli, Francesco ^c   Ferrarese, Alessia G ^d   de Caridi, Giovanni ^c   Gallelli, Luca ^a   de Franciscis, Stefano ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b S ANNA HOSPITAL   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

Author keywords

Chronic venous ulceration; Diosmin; MMPs; Nutraceutical; Patients

Indexed keywords

AXAVEN; GELATINASE A; GELATINASE B; INTERLEUKIN 6; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; NEUTROPHIL COLLAGENASE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; NUTRACEUTICAL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CHRONIC VEIN INSUFFICIENCY; CHRONIC VENOUS ULCERATION; COMPRESSION STOCKING; COMPRESSION THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PARALLEL DESIGN; PHLEBECTOMY; PRIORITY JOURNAL; ULCER; VEIN DISEASE; VEIN STRIPPING; WOUND HEALING;

EID: 84894339424     PISSN: 17424801     EISSN: 1742481X     Source Type: Journal    
DOI: 10.1111/iwj.12240     Document Type: Article

References (71)

1. Serra R, Buffone G, de Franciscis A, Mastrangelo D, Molinari V, Montemurro R, de Franciscis S. A genetic study of chronic venous insufficiency. Ann Vasc Surg 2012;26:636-42.
2. de Franciscis S, De Sarro G, Longo P, Buffone G, Molinari V, Stillitano DM, Gallelli L, Serra R. Hyperhomocysteinaemia and chronic venous ulcers. Int Wound J 2013. doi: 10.1111/iwj.12042 [Epub ahead of print].
3. Serra R, Buffone G, Costanzo G, Montemurro R, Perri P, Damiano R, de Franciscis S. Varicocele in younger as risk factor for inguinal hernia and for chronic venous disease in older: preliminary results of a prospective cohort study. Ann Vasc Surg 2013;27:329-31.
4. Serra R, Buffone G, Molinari V, Montemurro R, Perri P, Stillitano DM, Amato B, de Franciscis S. Low molecular weight heparin improves healing of chronic venous ulcers especially in the elderly. Int Wound J 2013. doi: 10.1111/iwj.12071 [Epub ahead of print].
5. Gasbarro V, Amato B, Izzo M, Manfrini A, Buffone G, Grande R, Serra R, De Franciscis S. Quercetin and chronic venous ulceration of the lower limbs. Acta Phlebol 2013;14:61-5.
6. Serra R, Buffone G, de Franciscis A, Mastrangelo D, Vitagliano T, Greco M, de Franciscis S. Skin grafting followed by low-molecular-weight heparin long-term therapy in chronic venous leg ulcers. Ann Vasc Surg 2012;26:190-7.
7. Serra R, Grande R, Buffone G, Costanzo G, Damiano R, de Franciscis S. Chronic venous disease is more aggressive in patients with varicocele. Acta Phlebol 2013;14:57-60.
8. de Franciscis S, Gasbarro V, Amato B, Buffone G, Grande R, Serra R. Haemodynamic surgery versus conventional surgery in chronic venous disease: a multicenter retrospective study. Acta Phlebol 2013;14:109-14.
9. de Franciscis S, Grande R, Buffone G, Serra R. Chronic venous ulceration of the lower limbs and thrombosis. Acta Phlebol 2013. In press.
10. Abd-El-Aleem SA, Morgan C, Ferguson MW, McCollum CN, Ireland GW. Spatial distribution of mast cells in chronic venous leg ulcers. Eur J Histochem 2005;49:265-72.
11. de Franciscis S, Gallelli L, Battaglia L, Molinari V, Montemurro R, Stillitano DM, Buffone G, Serra R. Cilostazol prevents foot ulcers in diabetic patients with peripheral vascular disease. Int Wound J 2013. doi: 10.1111/iwj.12085 [Epub ahead of print].
12. de Franciscis S, Mastroroberto P, Gallelli L, Buffone G, Montemurro R, Serra R. Increased plasma levels of metalloproteinase-9 and neutrophil gelatinase-associated lipocalin in a rare case of multiple artery aneurysm. Ann Vasc Surg 2013;27:1185.e5-7.
13. Busceti MT, Grande R, Amato B, Gasbarro V, Buffone G, Amato M, Gallelli L, Serra R, de Franciscis S. Pulmonary embolism, metalloproteinases and neutrophil gelatinase associated lipocalin. Acta Phlebol 2013;14:115-21.
14. Jung SA, Yang SK, Kim JS, Shim KN, Im SA, Myung SJ, Jung HY, Yu CS, Kim JC, Hong WS, Kim JH, Min YI. The expression of matrix metalloproteinases (MMPs), tissue inhibitor of metalloproteinases (TIMPs) and angiogenesis in relation to the depth of tumor invasion and lymph node metastasis in submucosally invasive colorectal carcinoma. Korean J Gastroenterol 2005;45:401-8.
15. Yang CC, Lin CY, Wang HS, Lyu SR. Matrix metalloproteases and tissue inhibitors of metalloproteinases in medial plica and pannus-like tissue contribute to knee osteoarthritis progression. PLoS One 2013;8:e79662.
16. Serra R, Buffone G, Costanzo G, Montemurro R, Scarcello E, Stillitano DM, Damiano R, de Franciscis S. Altered metalloproteinase-9 expression as the least common denominator between varicocele, inguinal hernia and chronic venous disorders. Ann Vasc Surg 2013, in press. doi: 10.1016/j.avsg.2013.07.026.
17. Amato B, Coretti G, Compagna R, Amato M, Buffone G, Gigliotti D, Grande R, Serra R, de Franciscis S. Role of matrix metalloproteinases in non-healing venous ulcers. Int Wound J 2013. doi: 10.1111/iwj.12181[Epub ahead of print].
18. Serra R, Buffone G, Falcone D, Molinari V, Scaramuzzino M, Gallelli L, de Franciscis S. Chronic venous leg ulcers are associated with high levels of metalloproteinases-9 and neutrophil gelatinase-associated lipocalin. Wound Repair Regen 2013;21:395-401.
19. Serra R, Grande R, Buffone G, Gallelli L, de Franciscis S. The effects of minocycline on extracellular matrix in patients with chronic venous leg ulcers. Act Phlebol 2013;14:99-107.
20. Serra R, Gallelli L, Buffone G, Molinari V, Stillitano DM, Palmieri C, de Franciscis S. Doxycycline speeds up healing of chronic venous ulcers. Int Wound J 2013. doi: 10.1111/iwj.12077[Epub ahead of print].
21. Weller C, Evans S. Venous leg ulcer management in general practice-practice nurses and evidence based guidelines. Aust Fam Physician 2012;41:331-7.
22. Belczak SQ, Sincos IR, Campos W, Beserra J, Nering G, Aun R. Venoactive drugs for chronic venous disease: A randomized, double-blind, placebo-controlled parallel-design trial. Phlebology 2013[Epub ahead of print].
23. Perrin M, Ramelet AA. Pharmacological treatment of primary chronic venous disease: rationale, results and unanswered questions. Eur J Vasc Endovasc Surg 2011;41:117-25.
24. Dholakiya SL, Benzeroual KE. Protective effect of diosmin on LPS-induced apoptosis in PC12 cells and inhibition of TNF-a expression. Toxicol In Vitro 2011;25:1039-44.
25. Carpentier PH, Mathieu M. Evaluation of clinical efficacy of a venotonic drug: lessons of a therapeutic trial with hemisynthesis diosmin in "heavy legs syndrome". J Mal Vasc 1998;23:106-12.
26. Jantet G. Chronic venous insufficiency: worldwide results of the RELIEF study. Reflux assEssment and quaLity of lIfe improvEment with micronized Flavonoids. Angiology 2002;53:245-56.
27. Alvarez N, Vicente V, Martínez C. Synergistic effect of diosmin and interferon-alpha on metastatic pulmonary melanoma. Cancer Biother Radiopharm 2009;24:347-52.
28. Manuel y KB, Vertommen J, De Leeuw I. The effect of flavonoid treatment on the glycation and antioxidant status in Type 1 diabetic patients. Diabetes Nutr Metab 1999;12:256-63.
29. Parker-Athill E, Luo D, Bailey A, Giunta B, Tian J, Shytle RD, Murphy T, Legradi G, Tan J. Flavonoids, a prenatal prophylaxis via targeting JAK2/STAT3 signaling to oppose IL-6/MIA associated autism. J Neuroimmunol 2009;217:20-7.
30. Kirienko AI, Bogachev VI, Zolotukhin IA, Golovanova OV. Semisynthetic diosmin (phlebodia 600) for therapy of lower limb chronic venous insufficiency. Angiol Sosud Khir 2006;12:73-5.
31. Gohel MS, Davies AH. Pharmacological agents in the treatment of venous disease: an update of the available evidence. Curr Vasc Pharmacol 2009;7:303-8.
32. Smith PC. Daflon 500 mg and venous leg ulcer: new results from a meta-analysis. Angiology 2005;56(Suppl 1):S33-9.
33. Cesarone MR, Belcaro G, Pellegrini L, Ledda A, Vinciguerra G, Ricci A, Di Renzo A, Ruffini I, Gizzi G, Ippolito E, Fano F, Dugall M, Acerbi G, Cornelli U, Hosoi M, Cacchio M. Venoruton vs Daflon: evaluation of effects on quality of life in chronic venous insufficiency. Angiology 2006;57:131-8.
34. Petruzzellis V, Troccoli T, Candiani C, Guarisco R, Lospalluti M, Belcaro G, Dugall M. Oxerutins (Venoruton): efficacy in chronic venous insufficiency - a double-blind, randomized, controlled study. Angiology 2002;53:257-63.
35. Giacalone M, Di Sacco F, Traupe I, Topini R, Forfori F, Giunta F. Antioxidant and neuroprotective properties of blueberry polyphenols: a critical review. Nutr Neurosci 2011;14:119-25.
36. Pashkow FJ, Watumull DG, Campbell CL. Astaxanthin: a novel potential treatment for oxidative stress and inflammation in cardiovascular disease. Am J Cardiol 2008;101:58D-68.
37. Bombardelli E, Morazzoni P. Aesculus hippocastanum L. Fitoterapia 1996;67:483-511.
38. Mrwa U, Güth K, Haist C, Troschka M, Herrmann R, Wojciechowski R, Gagelmann M. Calcium-requirement for activation of skinned vascular smooth muscle from spontaneously hypertensive (SHRSP) and normotensive control rats. Life Sci 1986;38:191-6.
39. Elbein AD, Pan YT, Pastuszak I, Carroll D. New insights on trehalose: a multifunctional molecule. Glycobiology 2003;13:17R-27.
40. Jain NK, Roy I. Effect of trehalose on protein structure. Protein Sci 2009;18:24-36.
41. Chen F, Fukuse T, Hasegawa S, Bando T, Hanaoka N, Kawashima M, Sakai H, Hamakawa H, Fujinaga T, Nakamura T, Wada H. Effective application of ET-Kyoto solution for clinical lung transplantation. Transplant Proc 2004;36:2812-5.
42. Eklof B, Rutherford RB, Bergan JJ, Carpentier PH, Gloviczki P, Kistner RL, Meissner MH, Moneta GL, Myers K, Padberg FT, Perrin M, Ruckley CV, Smith PC, Wakefield TW, American Venous Forum International Ad Hoc Committee for Revision of the CEAP Classification. Revision of the CEAP classification for chronic venous disorders: consensus statement. J Vasc Surg 2004;40:1248-52.
43. Fragomeni G, Merola A, Serra R, de Franciscis S, Amato F. A nonlinear lumped parameters model to analyze the dynamics of venous reflux. Conf Proc IEEE Eng Med Biol Soc. 2008;2008:1407-10.
44. de Franciscis S, Fragomeni J, Caruso MV, de Franciscis A, Perri P, Serra R. A new photographic computerized measurement system for chronic wound assessment. Acta Phlebol. 2013. In press.
45. Howard DP, Howard A, Kothari A, Wales L, Guest M, Davies AH. The role of superficial venous surgery in the management of venous ulcers: a systematic review. Eur J Vasc Endovasc Surg 2008;36:458-65.
46. Alden PB, Lips EM, Zimmerman KP, Garberich RF, Rizvi AZ, Tretinyak AS, Alexander JQ, Dorr KM, Hutchinson M, Isakson SL. Chronic venous ulcer: minimally invasive treatment of superficial axial and perforator vein reflux speeds healing and reduces recurrence. Ann Vasc Surg 2013;27:75-83.
47. Gloviczki P, Gloviczki ML. Evidence on efficacy of treatments of venous ulcers and on prevention of ulcer recurrence. Perspect Vasc Surg Endovasc Ther 2009;21:259-68.
48. Gloviczki P, Comerota AJ, Dalsing MC, Eklof BG, Gillespie DL, Gloviczki ML, Lohr JM, McLafferty RB, Meissner MH, Murad MH, Padberg FT, Pappas PJ, Passman MA, Raffetto JD, Vasquez MA, Wakefield TW, Society for Vascular Surgery, American Venous Forum. The care of patients with varicose veins and associated chronic venous diseases: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum. J Vasc Surg 2011;53(5 Suppl):2S-48.
49. Gloviczki P, Gloviczki ML. Guidelines for the management of varicose veins. Phlebology 2012;27(Suppl 1):2-9.
50. Coleridge-Smith P, Lok C, Ramelet AA. Venous leg ulcer: a meta-analysis of adjunctive therapy with micronized purified flavonoid fraction. Eur J Vasc Endovasc Surg 2005;30:198-208.
51. Yang B, Kotani A, Arai K, Kusu F. Estimation of the antioxidant activities of flavonoids from their oxidation potentials. Anal Sci 2001;17:599-604.
52. Amić D, Davidović-Amić D, Beslo D, Rastija V, Lucić B, Trinajstić N. SAR and QSAR of the antioxidant activity of flavonoids. Curr Med Chem 2007;14:827-45.
53. Gomes A, Fernandes E, Lima JL, Mira L, Corvo ML. Molecular mechanisms of anti-inflammatory activity mediated by flavonoids. Curr Med Chem 2008;15:1586-605.
54. Pietta PG. Flavonoids as antioxidants. J Nat Prod 2000;63:1035-42.
55. Barreca D, Laganà G, Bruno G, Magazù S, Bellocco E. Diosmin binding to human serum albumin and its preventive action against degradation due to oxidative injuries. Biochimie 2013;95:2042-9.
56. Campanero MA, Escolar M, Perez G, Garcia-Quetglas E, Sadaba B, Azanza JR. Simultaneous determination of diosmin and diosmetin in human plasma by ion trap liquid chromatography-atmospheric pressure chemical ionization tandem mass spectrometry: Application to a clinical pharmacokinetic study. J Pharm Biomed Anal 2010;51:875-81.
57. Ramelet AA. Clinical benefits of Daflon 500 mg in the most severe stages of chronic venous insufficiency. Angiology 2001;52(Suppl 1):S49-56.
58. Pittler MH, Ernst E. Horse chestnut seed extract for chronic venous insufficiency. Cochrane Database Syst Rev 2012;11:CD003230.
59. Higley HR, Ksander GA, Gerhardt CO, Falanga V. Extravasation of macromolecules and possible trapping of transforming growth factor-beta in venous ulceration. Br J Dermatol 1995;132:79-85.
60. Serra R, Grande R, Buffone G, Molinari V, Perri P, Perri A, Amato B, Colosimo M, de Franciscis S. Extracellular matrix assessment of infected chronic venous leg ulcers: role of metalloproteinases and inflammatory cytokines. Int Wound J 2014 Accepted.
61. Shoab SS, Scurr JH, Coleridge-Smith PD. Plasma VEGF as a marker of therapy in patients with chronic venous disease treated with oral micronised flavonoid fraction - a pilot study. Eur J Vasc Endovasc Surg 1999;18:334-8.
62. Stvrtinova V, Jahnova E, Weissova S, Horvathova M, Ferencik M. Inflammatory mechanisms involving neutrophils in chronic venous insufficiency of lower limbs. Bratisl Lek Listy 2001;102:235-9.
63. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999;274:21491-4.
64. Riccioni G, Speranza L, Pesce M, Cusenza S, D'Orazio N, Glade MJ. Novel phytonutrient contributors to antioxidant protection against cardiovascular disease. Nutrition 2012;28:605-10.
65. Karppi J, Rissanen TH, Nyyssönen K, Kaikkonen J, Olsson AG, Voutilainen S, Salonen JT. Effects of astaxanthin supplementation on lipid peroxidation. Int J Vitam Nutr Res 2007;77:3-11.
66. Manago S, Yonehara S. TNF family (TNF alpha, beta, FasL, CD40L). Nihon Rinsho 2005;63(Suppl 4):202-6.
67. Matchett MD, MacKinnon SL, Sweeney MI, Gottschall-Pass KT, Hurta RA. Blueberry flavonoids inhibit matrix metalloproteinase activity in DU145 human prostate cancer cells. Biochem Cell Biol 2005;83:637-43.
68. Berg K, Andersen H, Owen TC. The regulation of rhinovirus infection in vitro by IL-8, HuIFN-alpha, and TNF-alpha. APMIS 2004;112:172-82.
69. Park JS, Chyun JH, Kim YK, Line LL, Chew BP. Astaxanthin decreased oxidative stress and inflammation and enhanced immune response in humans. Nutr Metab (Lond) 2010;7:18.
70. Suzuki Y, Ohgami K, Shiratori K, Jin XH, Ilieva I, Koyama Y, Yazawa K, Yoshida K, Kase S, Ohno S. Suppressive effects of astaxanthin against rat endotoxin-induced uveitis by inhibiting the NF-kappa B signaling pathway. Exp Eye Res 2006;82:275-81.
71. Speranza L, Pesce M, Patruno A, Franceschelli S, de Lutiis MA, Grilli A, Felaco M. Astaxanthin treatment reduced oxidative induced pro-inflammatory cytokines secretion in U937: SHP-1 as a novel biological target. Mar Drugs 2012;10:890-9.